Compare Amylx Pharmaceuticals Inc (AMLX) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs JPMorgan Equity Premium Income ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.7 (market cap $2.64B), while JPMorgan Equity Premium Income ETF trades at $57.84. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | JEPI | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $24.19 | $59.88 |
52-Week Low | $7.82 | $55.29 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
JEPI trades at $57.8, up 0.28% today, with a bullish technical signal driven by moving averages. The ETF focuses on generating income through covered calls, offering monthly dividends, but key valuation ratios are not publicly disclosed. Recent news highlights its popularity among retirees for yield, though some articles note underperformance versus peers.
Outlook is mixed: strong income appeal supports demand, but competition and potential tax inefficiencies pose risks. Investors should weigh the high yield against total return lag and market volatility exposure. The bullish technical trend may face resistance near current levels if overbought conditions persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
